Children’s Hospital Reduces Viral Infections by 44% with UV-C Technology

A new study published in the American Journal of Infection Control shows how St. Mary’s Hospital for Children used the Clorox Healthcare Optimum-UV System to dramatically lower rates of viral infection among vulnerable pediatric patients, achieving a 44 percent reduction in viral infections over a 12-month period.

Advertisement

St. Mary’s Hospital for Children is a specialized pediatric facility located in Bayside New York that treats children with medically complex conditions, a population at especially high risk of contracting viral infections. Pediatric populations already face a heightened risk for respiratory illnesses caused by viruses such as influenza, rhinovirus, enterovirus and human metapneumonvirus (HMPV). Because many of St. Mary’s patients have weakened immune systems due to existing illness, preventing infections and outbreaks is even more critical. To help, the team took a new approach to an old problem: using ultraviolet UV-C technology to enhance traditional cleaning and disinfecting protocols.

Automated systems that use UV-C, the highest-energy form of ultraviolet light, to kill pathogens by inactivating their DNA, provide an extra layer of protection and are used to reach areas of the healthcare environment that may otherwise be missed or insufficiently addressed due to human error.

From February 2016 to January 2017, St. Mary’s included the Clorox Healthcare® Optimum-UV® System as an adjunct to standard cleaning protocols on the toddler unit, the area of the hospital that typically experienced the highest rates of infection. The system was used two to three times per week in patient rooms and bathrooms and three times per week in common areas. No other new interventions were introduced during this time.

The results were dramatic. Infection incidence data from the 12-month study period showed that use of the UV-C system resulted in a 44 percent reduction in viral infections caused by influenza, rhinovirus, enterovirus and HMPV compared to the prior 12-month period when UV-C was not used. Interestingly the findings also showed that UV-C had a potentially compounding benefit when used over a period of time, suggesting that each month’s UV-C use builds on the pathogen reduction benefit of use during the previous month.

Source: “The Impact of Ultraviolet-C Technology on Viral Infection Incidence in a Pediatric Long Term Care Facility.” American Journal of Infection Control (March 2018)  Click here to read the full report>>

 

News From Our Partners

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The 2 KPIs that drive readmissions — and how hospitals act on them in real time

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenter: Nik Rao, Dexur

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.